Erin

Carroll

"I evaluate the specific legal issues, risks and hurdles my clients face, while trying to keep their wider corporate and business goals in mind."

"I evaluate the specific legal issues, risks and hurdles my clients face, while trying to keep their wider corporate and business goals in mind."

Education
  • Columbia Law School, J.D., Harlan Fiske Stone Scholar, 2013
  • Colby College, B.A. in English, summa cum laude, Phi Beta Kappa, 2008

Recognitions
Community
Outside Interests

Erin Carroll helps entrepreneurs, high-growth companies and private equity firms successfully complete mergers and acquisitions, private equity transactions and investments.

experience

Erin Carroll has a range of both company and investment-side representation, as well as both private and public company experience. Her work has ranged in size from large M&A, Capital Markets and Emerging Company transactions, often involving over $100 million in consideration, to restructuring a 501(c)(3)’s corporate governance documents on a pro-bono basis.She enjoys acting as a strategic partner for her clients, providing ongoing corporate counsel and crafting creative solutions to legal problems, both large and small. Her genuine interest in people, natural curiosity about the businesses her clients run, and life-long love of both learning and problem solving—combined with an intense attention to detail—make her a successful advocate for her clients.

 

Erin joined the Feinberg Hanson team in August, 2018. Prior to joining Feinberg Hanson LLP, Erin had been an associate in the corporate department of Latham & Watkins LLP’s Boston office, where she focused mainly on Life Sciences and emerging technology clients. Erin has been admitted to the New York and Massachusetts bars.  

Below are some examples of Erin’s transactional experience:

  • Radius Health, Inc. (NASDAQ: RDUS), in connection with its     public follow-on equity offering of 4,600,000 shares of its common stock     at a public offering price of $36.75 per share, representing an offering     size of $169,050,000 in the aggregate.
  • HeartWare International, Inc. (NASDAQ: HTWR) (which was subsequently     purchased by Medtronic Plc (NYSE: MDT)), in its public cross-border     acquisition of Valtech Cardio, Ltd, an Israel-based medical device     company, for consideration and payments including: $368,412,000     consideration at the closing of the acquisition; $125,595,000 contingent     consideration, upon Valtech’s hitting certain regulatory approval     milestones with respect to its products; and $375,000,000 earn-out     payments, upon Valtech’s hitting certain sales revenue milestones for such     products.
  • Monsanto Company (NYSE: MON), in connection with the     renegotiation and amendment of its combined equity investment and option     transactions with Preceres LLC, a company that is researching novel     approaches to biological pest, virus and weed control. This transaction     involved renegotiation and amendments with respect to a complex series of     staged equity investments tied to milestones, combined with a purchase     option and service agreements.   
  • Boston Scientific Corporation (NYSE: BSX), in connection with its     $65,000,000 acquisition of IoGyn, Inc. and other strategic investments and     acquisitions.
  • Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA), in connection with its     cross-border formation (in Bermuda and the United States, respectively)     and its $40,000,000 Series A financing.
  • First Aid Beauty, Limited, in connection with an     investment made by Castanea Partners, a Boston-based private equity firm.
  • Great Hill Partners, a Boston-based private equity firm, in connection with     its acquisition of YogaWorks, a Los Angeles-based leading provider of     progressive and quality yoga, with 29 studios across four markets.
  • Palladin Consumer Retail Partners, LLC, a Boston-based private     equity firm, in connection with its acquisition of a majority interest in     Harry’s of London, a London-based luxury shoemaker and accessories house.
  • Morgan Stanley & Co. LLC, Credit Suisse Securities     (USA) LLC, UBS Securities LLC and Nomura Securities International, Inc., as designated     underwriters’ counsel, in connection with the initial public     offering of Akebia Therapeutics, Inc. (NASDAQ: AKBA), in which the     underwriters purchased 6,762,000 shares of common stock at a public     offering price of $17.00 per share, representing an IPO size of     $114,954,000 in the aggregate.
  • UBS Securities LLC, Morgan Stanley & Co. LLC, JMP     Securities LLC, Needham & Company, LLC and Brean Capital, LLC, as designated     underwriters’ counsel, in connection with a public follow-on equity     offering by Akebia Therapeutics, Inc. (NASDAQ: AKBA), in which the     underwriters purchased 8,363,636 shares of common stock at a public     offering price of $8.25 per share, representing an offering size of     $68,999,997 in the aggregate. This follow-on offering was pursuant to a     shelf registration statement filed with the SEC on Form S-3, under which     Akebia Therapeutics, Inc. had registered shelf offerings of up to     $160,000,000 worth of its common stock.
  • RBC Capital Markets, LLC, William Blair & Company,     L.L.C., Cantor Fitzgerald & Co. and Janney Montgomery Scott LLC, as designated     underwriters’ counsel, in connection with the initial public     offering of Agile Therapeutics, Inc. (NASDAQ: AGRX), in which the     underwriters purchased 9,166,667 shares of common stock at a public     offering price of $6.00 per share, representing an IPO size of $55,000,02     in the aggregate.
  • William Blair & Company, L.L.C., RBC Capital     Markets, LLC, Janney Montgomery Scott LLC and Cantor Fitzgerald & Co.,     as     designated underwriters’ counsel, in connection with a public     follow-on equity offering of Agile Therapeutics, Inc. (NASDAQ: AGRX), in     which the underwriters purchased 5,511,812 shares of common stock at a     public offering price of $6.35 per share, representing an offering size of     $35,000,06 in the aggregate.
  • Aratana Therapeutics, Inc. (NASDAQ: PETX), in connection with its     public follow-on equity offering of up to 6,325,000 shares of its common     stock at a public offering price of $19.00 per share, representing a     maximum offering size of $120,175,000 in the aggregate.

Education
  • Columbia Law School, J.D., Harlan Fiske Stone Scholar, 2013
  • Colby College, B.A. in English, summa cum laude, Phi Beta Kappa, 2008

Recognitions
Community
Outside Interests